Boehringer Ingelheim
Last updated on 2013-11-20T06:39+0300.
About this
image
License:
UNKNOWN
| Key Titles and Phrases | Count | Lang | Last Seen |
|---|---|---|---|
| farmacêutica alemã | 40.00% | PT | 29/12/2016 |
| farmacêutica | 20.00% | PT | 24/05/2016 |
| manufacturer | 20.00% | EN | 23/03/2015 |
| german manufacturer | 20.00% | EN | 23/03/2015 |
| Names | Lang | Count |
|---|---|---|
| Boehringer Ingelheim | EN | 61.60% |
| Boehringer Ingelheim | FR | 14.81% |
| Boehringer Ingelheim Pharmaceuticals | EN | 3.55% |
| Boehringer Ingelheim | PT | 3.10% |
| Boehringer Ingelheim | ES | 2.34% |
| Boehringer Ingelheim | PL | 2.19% |
| Boehringer Ingelheim | DE | 2.19% |
| Boehringer Ingelheim | IT | 2.12% |
| Boehringer Ingelheim | EU | 2.04% |
| Boehringer Ingelheim | SV | 2.04% |
| Boehringer-Ingelheim | EN | 1.74% |
| Boehringer-Ingelheim | FR | 1.51% |
| Boehringer-Ingelheim Pharmaceuticals | EN | 0.23% |
| Boehringer Ingelheim | AR | 0.15% |
| BOEHRINGER INGELHEIM | EN | 0.08% |
| Boehringer-Ingelheim Pharmaceuticals | FR | 0.08% |
| Boehringer Ingelheim Pharmaceuticals | PT | 0.08% |
| Boehringer Ingelheim Pharmaceuticals | ES | 0.08% |
| Boehringer-Ingelheim | DE | 0.08% |
| ベーリンガーインゲルハイム | JA | 0.00% |
| 勃林格殷格翰 | ZH | 0.00% |
| Type | Entity Name | Count |
|---|---|---|
 | Inc | 5.94% |
| Pfizer Inc | 4.12% |
| Novartis | 3.42% |
| Eli Lilly | 2.11% |
| Bristol Myers Squibb | 2.01% |
| Novo Nordisk | 1.91% |
 | Laura Wood | 1.91% |
| Commission | 1.81% |
| Pharmaceuticals Inc | 1.61% |
| European Union | 1.51% |
| Teva Pharmaceuticals | 1.31% |
| Strategy | 1.31% |
| GlaxoSmithKline | 1.21% |
| European Commission | 1.21% |
| 1.11% | |
| Product Development | 1.11% |
| European Medicines Agency | 1.11% |
| Dr Reddy | 1.01% |
| Drug Administration | 1.01% |
| Samsung | 1.01% |
| World Health Organization | 0.91% |
| Saudi | 0.91% |
| Association | 0.91% |
| SA | 0.91% |
| Risk Factors | 0.80% |
| Solutions | 0.80% |
| Five Forces | 0.70% |
| United Nations | 0.60% |
| Wall Street | 0.60% |
| Market Development | 0.60% |
| Type | Entity Name | Score |
|---|---|---|
| Novartis | 0.0322 |
| Thomas Schmitz | 0.0215 |
| Rath Health Foundation | 0.0208 |
| Bristol Myers Squibb | 0.0201 |
| Novo Nordisk | 0.02 |
| Eli Lilly | 0.019 |
| Laura Wood | 0.0157 |
| Pharmaceuticals Inc | 0.015 |
| Paul Wynn | 0.0149 |
| Teva Pharmaceuticals | 0.0129 |
| Product Development | 0.0115 |
| GlaxoSmithKline | 0.0104 |
| Dr Reddy | 0.0097 |
| European Medicines Agency | 0.0094 |
| Pfizer Inc | 0.0082 |
| 0.0082 | |
| Strategy | 0.008 |
| Samsung | 0.008 |
| West Brabant | 0.008 |
| Inc | 0.0079 |
| Eric van den Berg | 0.0074 |
| Maryvonne Hiance | 0.0073 |
| Five Forces | 0.0066 |
| Risk Factors | 0.0063 |
| Market Development | 0.0062 |
| Drug Administration | 0.0061 |
| Dominique Costantini | 0.006 |
| Thermo Fisher Scientific | 0.0056 |
| Fred Reichheld | 0.0052 |
| Medicines Agency | 0.0051 |
Show/hide duplicate news articles.
Show/hide duplicate news articles.
Tools
Sunday, February 5, 2023
5:01:00 AM EAT
Languages 
Select your languages
Explore Relations
Please send any comments or suggestions to 